BMSC-derived EVs elevated miR-34a levels, reducing RA inflammation and inhibiting RA-FLS proliferation by targeting the cyclin I/p53/ataxia-telangiectasia mutated signaling pathway (153). This evidence concerns the gene TP53 and rheumatoid arthritis.